528 related articles for article (PubMed ID: 25930159)
1. Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.
Pietropaolo V; Bellizzi A; Anzivino E; Iannetta M; Zingaropoli MA; Rodio DM; Morreale M; Pontecorvo S; Francia A; Vullo V; Palamara AT; Ciardi MR
J Neurovirol; 2015 Dec; 21(6):653-65. PubMed ID: 25930159
[TBL] [Abstract][Full Text] [Related]
2. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.
Delbue S; Elia F; Carloni C; Pecchenini V; Franciotta D; Gastaldi M; Colombo E; Signorini L; Carluccio S; Bellizzi A; Bergamaschi R; Ferrante P
J Neurovirol; 2015 Dec; 21(6):645-52. PubMed ID: 25052191
[TBL] [Abstract][Full Text] [Related]
3. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
Werner MH; Huang D
J Neurovirol; 2016 Dec; 22(6):871-875. PubMed ID: 27198748
[TBL] [Abstract][Full Text] [Related]
5. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
Zingaropoli MA; Iannetta M; Pontecorvo S; Anzivino E; Prezioso C; Rodio DM; Morreale M; D'Abramo A; Oliva A; Lichtner M; Cortese A; Frontoni M; Pietropaolo V; Francia A; Mastroianni CM; Vullo V; Ciardi MR
Biomed Res Int; 2018; 2018():5297980. PubMed ID: 29682547
[TBL] [Abstract][Full Text] [Related]
6. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A
J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788
[TBL] [Abstract][Full Text] [Related]
7. Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study.
Bellizzi A; Anzivino E; Rodio DM; Cioccolo S; Scrivo R; Morreale M; Pontecorvo S; Ferrari F; Di Nardo G; Nencioni L; Carluccio S; Valesini G; Francia A; Cucchiara S; Palamara AT; Pietropaolo V
Virol J; 2013 Sep; 10():298. PubMed ID: 24079660
[TBL] [Abstract][Full Text] [Related]
8. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
[TBL] [Abstract][Full Text] [Related]
9. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
10. JC virus viremia in interferon-beta -treated and untreated Italian multiple sclerosis patients and healthy controls.
Delbue S; Guerini FR; Mancuso R; Caputo D; Mazziotti R; Saresella M; Ferrante P
J Neurovirol; 2007; 13(1):73-7. PubMed ID: 17454451
[TBL] [Abstract][Full Text] [Related]
11. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.
Chalkias S; Dang X; Bord E; Stein MC; Kinkel RP; Sloane JA; Donnelly M; Ionete C; Houtchens MK; Buckle GJ; Batson S; Koralnik IJ
Ann Neurol; 2014 Jun; 75(6):925-34. PubMed ID: 24687904
[TBL] [Abstract][Full Text] [Related]
12. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ
N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227
[TBL] [Abstract][Full Text] [Related]
13. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
Schweitzer F; Ladwig A; Opala S; Laurent S; Schroeter M; Goelz S; Fink GR; Wieland U; Silling S; Warnke C
Mult Scler Relat Disord; 2024 Jul; 87():105664. PubMed ID: 38735204
[TBL] [Abstract][Full Text] [Related]
14. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Rudick RA; O'Connor PW; Polman CH; Goodman AD; Ray SS; Griffith NM; Jurgensen SA; Gorelik L; Forrestal F; Sandrock AW; Goelz SE
Ann Neurol; 2010 Sep; 68(3):304-10. PubMed ID: 20737514
[TBL] [Abstract][Full Text] [Related]
15. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME
J Neurol Sci; 2024 Jun; 461():123046. PubMed ID: 38761670
[TBL] [Abstract][Full Text] [Related]
16. JCV detection in multiple sclerosis patients treated with natalizumab.
Sadiq SA; Puccio LM; Brydon EW
J Neurol; 2010 Jun; 257(6):954-8. PubMed ID: 20052484
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
[TBL] [Abstract][Full Text] [Related]
18. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients.
Reid CE; Li H; Sur G; Carmillo P; Bushnell S; Tizard R; McAuliffe M; Tonkin C; Simon K; Goelz S; Cinque P; Gorelik L; Carulli JP
J Infect Dis; 2011 Jul; 204(2):237-44. PubMed ID: 21673034
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
20. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
Havla J; Berthele A; Kümpfel T; Krumbholz M; Jochim A; Kronsbein H; Ryschkewitsch C; Jensen P; Lippmann K; Hemmer B; Major E; Hohlfeld R
Mult Scler; 2013 Aug; 19(9):1213-5. PubMed ID: 23124790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
